LabConnect Expands North American Headquarters in Seattle
The success of LabConnect’s Scientific Operations Support (SciOps) team and overall company growth are behind its move to larger quarters in Seattle’s historic district.
“We needed to expand because we are growing,” said LabConnect President and Chief Executive Officer Eric Hayashi. “But beyond the additional space needed for our core office functions, we wanted to create just-in-time space for our growing SciOps team members who spend most of their time off site with clients. This move will give us room to double our capacity and allow us to better serve our clients.”
LabConnect provides central laboratory testing services to the biopharmaceutical industry through a global network of regional and local laboratories. The SciOps team is a special unit comprised of industry experts with a minimum of 10 years of experience who offer short- or long-term functional outsourcing services for pharmaceutical research.
“Our customers want to focus on getting the job done well, not on the human resources aspects,” Hayashi said. “We help with both. We provide experienced research professionals and take care of all the details such as payroll and benefits. Demand for this service has been strong since the beginning and it is still growing.”
LabConnect’s new headquarters is in Seattle’s historic Mutual Life Building at 605 First Ave., Ste. 300. Contact LabConnect at 206-322-4680 or by email at [email protected].
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
